PET and Hormone Receptor Ligands in Breast Cancer
Annual rept. 29 Apr 2004-28 Apr 2006
MEMORIAL SLOAN-KETTERING CANCER CENTER NEW YORK
Pagination or Media Count:
F-18 labeled estradiol has been found to be useful in the evaluation of estrogen receptor status in patients with breast cancer using PET. To investigate this further, this projects objectives are To evaluate the use of estrogen-like ligands labeled with positron emitters in preoperatively determining the ER status of breast cancer using PET. Correlate the ER positivity seen on PET imaging with ER positivity found on pathologic analysis of the surgical specimen. This proof-of-concept study is a pilot study designed to determine feasibility of PET imaging. If the study is positive, i.e. if more than 70 of ER lesions are positive on PET imaging, we will subsequently plan a study with outcome parameters. PET scans will be graded as negative or positive defined as tumornormal uptake ratios of 1.51 and ER status will also be graded as negative or positive defined as staining of 5 tumor cells in an average high power field. Paired t-test comparison of tumor HO and PET findings will be carried out. Gamma well counting will be used to quantify uptake of radioactivity in tumor and normal tissue including serum, and expressed as percent injected dosegram. Serum estradiol is being measured to observe a possible relationship between serum estradiol levels and targeting of radiotracer.
- Medicine and Medical Research
- Nuclear Physics and Elementary Particle Physics